GSK reveals two-dose Cervarix data
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has presented the Phase III data for its cervical cancer vaccine Cervarix (human papillomavirus (types 16 and 18) vaccine, recombinant) that supported its recent EU expanded approval application for use in a two-dose, rather than three-dose, schedule in some recipients.